Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 4/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.50 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | F7 | P08709 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | F3 | P13726 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.37 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29975686 | 1.00 | AHR (0.50) | AHRNR4A2CYP2A6CSNK2A1HDAC6 | |
| SCHEMBL29563719 | 0.83 | AHR (0.50) | AHRNR4A2CYP2A6CSNK2A1GPR84 | |
| SCHEMBL1513255 | 0.83 | AHR (0.50) | AHRNR4A2CYP2A6CSNK2A1GPR84 | |
| Ethoxycarbonyl Group SCHEMBL27658731 | 0.81 | CYP2A6 (0.36) | AHRNR4A2CYP2A6CSNK2A1HDAC6 | |
| SCHEMBL12680497 | 0.76 | NPC1 (0.56) | AHRNR4A2CYP2A6NPC1DYRK1B | |
| SCHEMBL8664673 | 0.75 | PDPK1 (0.47) | AHRNR4A2CYP2A6CSNK2A1HDAC6 | |
| SCHEMBL14041127 | 0.75 | GPR84 (0.52) | AHRNR4A2CYP2A6CSNK2A1HDAC6 | |
| SCHEMBL8296659 | 0.75 | CYP2A6 (0.47) | AHRNR4A2CYP2A6CSNK2A1HDAC6 | |
| SCHEMBL21090062 | 0.75 | HDAC6 (0.43) | AHRNR4A2CYP2A6CSNK2A1HDAC6 | |
| SCHEMBL30758727 | 0.75 | CYP2A6 (0.47) | AHRNR4A2CYP2A6CSNK2A1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720036-A1 | CYP26B1 INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | 16380026 Canada Inc. (CA) | 2026-04-08 | — | — | EP | disclosed |
| EP-4482583-B1 | ZWITTERIONIC ANTIBACTERIAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2026-04-01 | — | — | EP | disclosed |
| WO-2025151549-A1 | PYRIDO[3,2-B]INDOLE-3-CARBONITRILE COMPOUNDS AND COMPOSITION FOR TARGETING TP53-Y220C MUTANTS | FLARE THERAPEUTICS INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| US-20250179066-A1 | ZWITTERIONIC ANTIBACTERIAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-06-05 | — | — | US | disclosed |
| US-20250114345-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS | 2025-04-10 | — | — | US | disclosed |
| WO-2025049994-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2025-03-06 | — | — | WO | disclosed |
| WO-2024243692-A1 | CYP26B1 INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2024-12-05 | — | — | WO | disclosed |
| US-20240368168-A1 | SARM1 ENZYME ACTIVITY INHIBITOR AND APPLICATION THEREOF | ARTIVILA BIOPHARMA (CN) | 2024-11-07 | — | — | US | disclosed |
| US-20240279205-A1 | NOVEL BENZIMIDAZOLE DERIVATIVE | CARNA BIOSCIENCES, INC. (JP) | 2024-08-22 | — | — | US | disclosed |
| WO-2024148247-A2 | AZAINDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| US-20140018380-A1 | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 RECEPTOR AGONISTS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2014-01-16 | — | — | US | disclosed |
| US-20140018380-A1 | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 RECEPTOR AGONISTS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2014-01-16 | — | — | US | disclosed |
| EP-2670746-A1 | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 RECEPTOR AGONISTS | Centaurus Biopharma Co., Ltd. (CN) | 2013-12-11 | — | — | EP | disclosed |
| US-20130178486-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| WO-2013092940-A1 | 2, 4-DIAMINE-PYRIMIDINE DERIVATIVE AS SERINE/THREONINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| US-20120245344-A1 | GPR119 AGONIST | NIPPON CHEMIPHAR CO., LTD. (JP) | 2012-09-27 | — | — | US | disclosed |
| WO-2012103806-A1 | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 RECEPTOR AGONISTS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2012-08-09 | — | — | WO | disclosed |
| WO-2012103806-A1 | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 RECEPTOR AGONISTS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2012-08-09 | — | — | WO | disclosed |
| CN-102617548-A | Bicycloheteroaryl compounds as GPR Receptor stimulant, compositions and application thereof | BEIJING CENTAURUS BIOPHARMA TECHNOLOGY CO LTD | 2012-08-01 | — | — | CN | disclosed |
| EP-2474540-A1 | GPR119 AGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018380-A1 | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 RECEPTOR AGONISTS | GPR119, GPR88, GPR84 | AHR 227/4885NR4A2 131/4885CYP2A6 935/4885 |
| US-20130178486-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, AKT1, PAK3 | AHR 4073/4885NR4A2 2917/4885CYP2A6 4751/4885 |
| US-20250179066-A1 | ZWITTERIONIC ANTIBACTERIAL COMPOUNDS | MRPL21, WIZ, CFTR | AHR 3310/4885NR4A2 3876/4885CYP2A6 2634/4885 |
| US-20250114345-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | EP300, CREBBP, HDAC1 | AHR 593/4885NR4A2 471/4885CYP2A6 2204/4885 |
| US-20240279205-A1 | NOVEL BENZIMIDAZOLE DERIVATIVE | STING1, IRF3, TBK1 | AHR 2822/4885NR4A2 2409/4885CYP2A6 2833/4885 |
| US-20240368168-A1 | SARM1 ENZYME ACTIVITY INHIBITOR AND APPLICATION THEREOF | SARM1, BACE1, SARNP | AHR 2818/4885NR4A2 3534/4885CYP2A6 1467/4885 |
| US-20120245344-A1 | GPR119 AGONIST | GPR119, GPR4, GPR55 | AHR 182/4885NR4A2 81/4885CYP2A6 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.